However, one third of pDC-AML cases in our study did not carry RUNX1 mutations, and these RUNX1 wild type cases showed significantly more frequent TP53 mutations, less DNMT3A mutations and conspicuously more frequent CD2 expression on pDCs (68%). This evidence concerns the gene DNMT3A and acute myeloid leukemia.